A
AcelRx Pharmaceuticals Inc
F:R5X
AcelRx Pharmaceuticals Inc
F:R5X
Price:
2.106
EUR
9.74%
Market Closed
Market Cap:
€310.3m
Balance Sheet
Balance Sheet Decomposition
AcelRx Pharmaceuticals Inc
AcelRx Pharmaceuticals Inc
Balance Sheet Decomposition is not available for
AcelRx Pharmaceuticals Inc
AcelRx Pharmaceuticals Inc
Balance Sheet
AcelRx Pharmaceuticals Inc
AcelRx Pharmaceuticals Inc
Currency: USD
| Dec-2013 | Dec-2014 | Dec-2015 | Dec-2016 | Dec-2017 | Dec-2018 | Dec-2019 | Dec-2020 | Dec-2021 | Dec-2022 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | |||||||||||
| Cash & Cash Equivalents |
88
|
60
|
108
|
80
|
53
|
88
|
15
|
27
|
8
|
15
|
|
| Cash Equivalents |
88
|
60
|
108
|
80
|
53
|
88
|
15
|
27
|
8
|
15
|
|
| Short-Term Investments |
15
|
15
|
6
|
0
|
8
|
18
|
52
|
16
|
39
|
1
|
|
| Total Receivables |
0
|
0
|
3
|
6
|
2
|
0
|
1
|
1
|
0
|
0
|
|
| Accounts Receivables |
0
|
0
|
3
|
6
|
2
|
0
|
0
|
1
|
0
|
0
|
|
| Other Receivables |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Inventory |
0
|
0
|
1
|
2
|
1
|
1
|
3
|
2
|
1
|
1
|
|
| Other Current Assets |
1
|
1
|
2
|
1
|
1
|
1
|
2
|
2
|
3
|
7
|
|
| Total Current Assets |
105
|
76
|
119
|
89
|
63
|
108
|
72
|
47
|
51
|
25
|
|
| PP&E Net |
5
|
10
|
9
|
11
|
11
|
12
|
19
|
19
|
20
|
14
|
|
| PP&E Gross |
5
|
10
|
9
|
11
|
11
|
12
|
19
|
19
|
20
|
14
|
|
| Accumulated Depreciation |
2
|
3
|
5
|
7
|
8
|
9
|
10
|
11
|
11
|
12
|
|
| Intangible Assets |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
9
|
|
| Note Receivable |
0
|
0
|
0
|
0
|
1
|
0
|
0
|
0
|
0
|
0
|
|
| Other Long-Term Assets |
0
|
0
|
0
|
0
|
0
|
1
|
1
|
1
|
7
|
0
|
|
| Total Assets |
110
N/A
|
86
-21%
|
128
+48%
|
100
-22%
|
76
-24%
|
121
+59%
|
91
-24%
|
66
-27%
|
78
+17%
|
48
-39%
|
|
| Liabilities | |||||||||||
| Accounts Payable |
2
|
2
|
2
|
2
|
1
|
2
|
2
|
3
|
2
|
2
|
|
| Accrued Liabilities |
4
|
4
|
4
|
5
|
4
|
5
|
7
|
6
|
8
|
6
|
|
| Short-Term Debt |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Current Portion of Long-Term Debt |
0
|
7
|
5
|
4
|
8
|
9
|
5
|
9
|
9
|
6
|
|
| Other Current Liabilities |
1
|
1
|
3
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Total Current Liabilities |
7
|
14
|
13
|
10
|
14
|
16
|
14
|
18
|
19
|
14
|
|
| Long-Term Debt |
14
|
18
|
16
|
19
|
11
|
3
|
21
|
13
|
5
|
0
|
|
| Other Liabilities |
16
|
8
|
66
|
77
|
87
|
97
|
99
|
91
|
90
|
12
|
|
| Total Liabilities |
37
N/A
|
40
+8%
|
95
+138%
|
105
+11%
|
112
+6%
|
116
+4%
|
133
+14%
|
122
-8%
|
114
-7%
|
26
-77%
|
|
| Equity | |||||||||||
| Common Stock |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Retained Earnings |
146
|
179
|
203
|
246
|
298
|
345
|
398
|
439
|
474
|
426
|
|
| Additional Paid In Capital |
219
|
225
|
236
|
241
|
261
|
349
|
357
|
383
|
438
|
448
|
|
| Other Equity |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Total Equity |
73
N/A
|
47
-36%
|
33
-29%
|
5
N/A
|
37
-589%
|
4
N/A
|
41
N/A
|
56
-35%
|
36
+36%
|
22
N/A
|
|
| Total Liabilities & Equity |
110
N/A
|
86
-21%
|
128
+48%
|
100
-22%
|
76
-24%
|
121
+59%
|
91
-24%
|
66
-27%
|
78
+17%
|
48
-39%
|
|
| Shares Outstanding | |||||||||||
| Common Shares Outstanding |
2
|
2
|
2
|
2
|
3
|
4
|
4
|
5
|
7
|
8
|
|
Switch to:
Switch to:
See Also
Discover More
